BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nguyen TT, Quach THT, Tran TM, Phuoc HN, Nguyen HT, Vo TK, Vo GV. Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. Biomed Pharmacother 2022;147:112650. [PMID: 35066301 DOI: 10.1016/j.biopha.2022.112650] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Kohmer N, Stein S, Schenk B, Grikscheit K, Metzler M, Rabenau HF, Widera M, Herrmann E, Wicker S, Ciesek S. Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study. Int J Infect Dis 2022;128:166-75. [PMID: 36587839 DOI: 10.1016/j.ijid.2022.12.034] [Reference Citation Analysis]
2 Li P, Wang W, Tao Y, Tan X, Li Y, Mao Y, Gao L, Feng L, Zhan S, Sun F. Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. Chin Med J (Engl) 2023. [PMID: 36723872 DOI: 10.1097/CM9.0000000000002567] [Reference Citation Analysis]
3 Mojadadi MS, Javadinia SA, Attarian F, Samami E, Sobhani M. Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination. Front Public Health 2022;10:960598. [PMID: 36711369 DOI: 10.3389/fpubh.2022.960598] [Reference Citation Analysis]
4 Golpour M, Mousavi T, Alizadeh-Navaei R, Mardomi A. The immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy individuals: A systematic review and meta-analysis. Transpl Immunol 2022;:101732. [PMID: 36328249 DOI: 10.1016/j.trim.2022.101732] [Reference Citation Analysis]
5 Pfrommer LR, Schoeps M, Blettner M, Wollschläger D, Herm-Stapelberg N, Mittnacht L, Kachel P, Jahn K, Loewenich FDV, Gianicolo EAL. Self-Reported Reactogenicity After Different COVID-19 Vaccination Regimens. Dtsch Arztebl Int 2022;119:727-34. [PMID: 35972414 DOI: 10.3238/arztebl.m2022.0298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Silva-Valencia J, Soto-Becerra P, Escobar-Agreda S, Fernandez-Navarro M, Elorreaga OA, Mayta-Tristán P, Mezones-Holguin E, Solari L. Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study using national population data. Vaccine 2022;40:6512-9. [PMID: 36202642 DOI: 10.1016/j.vaccine.2022.09.066] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Takano T, Sato T, Kotaki R, Moriyama S, Shinoda M, Kabasawa K, Shimada N, Kousaka M, Adachi Y, Onodera T, Terahara K, Isogawa M, Matsumura T, Shinkai M, Takahashi Y. Heterologous booster immunization with SARS-CoV-2 spike protein after mRNA vaccine elicits durable and broad antibody responses.. [DOI: 10.21203/rs.3.rs-2014078/v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Ahmed TI, Rishi S, Irshad S, Aggarwal J, Happa K, Mansoor S. Inactivated vaccine Covaxin/BBV152: A systematic review. Front Immunol 2022;13:863162. [PMID: 36016940 DOI: 10.3389/fimmu.2022.863162] [Reference Citation Analysis]
9 Almadhi M, Alawadhi A, Stevenson N, Greish K, Jawad J, Alsayyad A, Mirza A, Alsaffar B, Alalawi E, Fakhroo K, Alalawi B, Alabbasi L, Aljalahma N, Alqahtani M. Comparing the Safety and Immunogenicity of homologous (Sputnik V) and heterologous (BNT162B2) COVID-19 prime-boost vaccination.. [DOI: 10.1101/2022.08.24.22279160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zarębska-Michaluk D, Hu C, Brzdęk M, Flisiak R, Rzymski P. COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. Vaccines (Basel) 2022;10:1223. [PMID: 36016111 DOI: 10.3390/vaccines10081223] [Reference Citation Analysis]
11 Cheng H, Peng Z, Si S, Alifu X, Zhou H, Chi P, Zhuang Y, Mo M, Yu Y. Neutralization Activity against SARS-CoV-2 Variants after Booster Vaccination in Populations without COVID-19: A Meta-Analysis. Vaccines (Basel) 2022;10:1101. [PMID: 35891263 DOI: 10.3390/vaccines10071101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bhuiyan TR, Akhtar M, Khaton F, Rahman SIA, Ferdous J, Alamgir A, Rahman M, Kawser Z, Hasan I, Calderwood SB, Harris JB, Charles RC, Larocque RC, Ryan ET, Banu S, Shirin T, Qadri F. Covishield vaccine induces robust immune responses in Bangladeshi adults. IJID Regions 2022;3:211-217. [DOI: 10.1016/j.ijregi.2022.04.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Cheng H, Peng Z, Si S, Alifu X, Zhou H, Chi P, Zhuang Y, Mo M, Yu Y. Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis. Vaccines 2022;10:798. [DOI: 10.3390/vaccines10050798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
14 Rzymski P, Sikora D, Zeyland J, Poniedziałek B, Kiedik D, Falfushynska H, Fal A. Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine. Vaccines 2022;10:754. [DOI: 10.3390/vaccines10050754] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Jantarabenjakul W, Sodsai P, Chantasrisawad N, Jitsatja A, Ninwattana S, Thippamom N, Ruenjaiman V, Tan CW, Pradit R, Sophonphan J, Wacharapluesadee S, Wang L, Puthanakit T, Hirankarn N, Putcharoen O. Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers. Vaccines 2022;10:639. [DOI: 10.3390/vaccines10050639] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
16 Vo GV, Bagyinszky E, An SSA. COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development. Microorganisms 2022;10:598. [DOI: 10.3390/microorganisms10030598] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]